2024 European Society for Medical Oncology (ESMO) Annual Congress
ESMO 2024 Prostate Cancer
- ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
- ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304)
- ESMO 2024: HARMONY: A Phase II Study of Niraparib/Abiraterone Acetate plus Prednisone for Hispanic/Latinoand Non-Hispanic Black Patients with Metastatic Hormone Sensitive Prostate Cancer and Deleterious Homologous Recombination Repair Alterations
- ESMO 2024: A New Prognostic Model of Overall Survival (OS) in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- ESMO 2024: Hematologic Impact of [177Lu]Lu-PSMA-617 Versus ARPI Change in Patients with Metastatic Castration-Resistant Prostate Cancer in PSMAfore
ESMO 2024 Bladder Cancer
- ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Non-Prostate
- ESMO 2024: Identification of Bladder Cancer Patients That Could Benefit from Early Post-Cystectomy Immunotherapy Based on Serial Circulating Tumour DNA Testing: Preliminary Results from the TOMBOLA Trial
- ESMO 2024: Invited Discussant: JCOG1019, TOMBOLA, and SunRISe-4
- ESMO 2024: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Cisplatin-Based Chemotherapy: Interim Analysis of SunRISe-4
- ESMO 2024: Empowering Bladder Cancer Care Integrating Patient Preferences and Voices
ESMO 2024 Kidney Cancer
- ESMO 2024: NEOTAX: A Phase II Trial of Neoadjuvant Toripalimab plus Axitinib for Clear Cell Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
- ESMO 2024: Systemic Treatment Options
- ESMO 2024: Is There a Role for Radiation Therapy in Advanced RCC?
- ESMO 2024: The Role of Cytoreductive Nephrectomy in the Immunotherapy Era
- ESMO 2024: Novel Serum Glycoproteomic Biomarkers Predict Response to Nivolumab plus Cabozantinib Versus Sunitinib in Advanced RCC: Analysis from CheckMate 9ER
ESMO 2024 Testicular and Penile Cancer
- ESMO 2024: Controversies in Testis Cancer: Escalation or De-escalation?
- ESMO 2024: Updates in Penile Cancer
- ESMO 2024: Prospective COTRIMS (COlogne Trial of Retroperitoneal Lymphadenectomy in Metastatic Seminoma) Trial – 3 Year Update
- ESMO 2024: Assessment of the Utility of CT Scans in the Long-Term Follow-up of Metastatic Non-Seminomatous Germ Cell Tumors: The Late CT Study
ESMO 2024 Press Releases
- ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer
- Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
- ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
- Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
- AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024